Traws Pharma, Inc. (NASDAQ:TRAW) Given Average Recommendation of “Reduce” by Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have earned a consensus rating of “Reduce” from the five brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $1.00.

TRAW has been the topic of several research analyst reports. LADENBURG THALM/SH SH lowered Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Weiss Ratings downgraded Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. HC Wainwright restated a “negative” rating and set a $1.00 target price on shares of Traws Pharma in a research report on Thursday, June 18th. Wall Street Zen raised shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Citigroup cut shares of Traws Pharma to a “neutral” rating in a report on Monday, June 15th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. State Street Corp purchased a new stake in shares of Traws Pharma in the fourth quarter valued at about $29,000. Two Sigma Investments LP boosted its stake in shares of Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after buying an additional 5,955 shares during the period. XTX Topco Ltd grew its holdings in shares of Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after buying an additional 31,502 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Traws Pharma during the fourth quarter worth about $56,000. Finally, Geode Capital Management LLC increased its position in Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after acquiring an additional 18,213 shares during the period. 7.95% of the stock is currently owned by institutional investors and hedge funds.

Traws Pharma Price Performance

NASDAQ TRAW opened at $0.54 on Tuesday. The company has a fifty day moving average of $0.80 and a two-hundred day moving average of $1.42. The company has a market capitalization of $8.18 million, a PE ratio of -0.32 and a beta of 1.57. Traws Pharma has a 1 year low of $0.43 and a 1 year high of $3.27.

Traws Pharma (NASDAQ:TRAW) last posted its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.39. On average, research analysts expect that Traws Pharma will post -1.43 earnings per share for the current year.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.